Catalyst Wire Dossier Catalyst Wire Dossier

Sublingual immunotherapy tablet containing recombinant Bet v1

recombinant Bet v1 allergen · Stallergenes Greer
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sublingual immunotherapy tablet containing recombinant Bet v1, covering 2013-06-27 to 2013-06-27. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1 [Phase 1]

See pricing